drugset
drugset / Trial / NCT05972720

A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma

NCT05972720 ↗

Phase 2 Terminated 101 enrolled CARGO Therapeutics
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a prospective, open-label, multi-center clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of firicabtagene autoleucel (firi-cel), a CD22-directed autologous Chimeric Antigen Receptor (CAR) T-cell therapy for the treatment of relapsed or refractory large B-cell lymphoma (LBCL).

Timeline

Start
2023-08-01
Primary completion
2025-04-04
Completion
2025-04-04

Outcome

Outcome not reported

Stopped: “Company decision to stop trial, withdraw the IND and close down operations.”

Drugs

EvaluationDrugModalityDoseRoute
Subject firicabtagene autoleucel Unknown — —
Background Cyclophosphamide Other / unclassified — —
Background Fludarabine Small molecule — —

Indications

cancer large B-cell lymphoma